

Aurinia Pharmaceuticals Inc. (AUPH)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001600620

Aurinia Pharmaceuticals Inc. AUPH; healthcare	
Grade	A strongest fifth of 371 graded peers percentile 17.3; sampling error 2.5 points; lower is stronger
Rank	65 of 371
Profitability	D percentile 67.0
Solvency	B percentile 26.3
Growth and financing	A/B percentile 17.7
Reliability	0.91 AUC filers with \$591M to \$2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$591M to \$2.67B assets total assets \$751.6M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active not computable: distress, fortress balance sheet
Inputs computable	8 of 14
Graded from	filings received through Feb 26, 2026 225 days before the rescans; latest periodic filing 10-Q received Aug 6, 2026
Last close	\$16.22 2026-10-08; market equity \$2.2B
Price used in grade	None

A, the bull
strongest fifth of its sector;
letters are fifths of the 371
graded peers

Share price, twelve months to the rescans
split-adjusted close; the letter is fixed at the rescans that set it

Rescans on file: A from Mar 21, 2025, A from Mar 21, 2026, A/B from May 21, 2026

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Feb 26, 2026

Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis ("LN"). Aurinia is also developing aritinercept, a dual inhibitor of B cell-activating factor ("BAFF") and a proliferation-inducing ligand ("APRIL") for the potential treatment of autoimmune diseases.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 67.0						
Gross profitability		33.3%	32.2%	43.4	372	2025-12-31
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		23.3%	(6.6%)	95.7	811	2025-12-31
Gross margin stability, five years		3.8 pts	2.8 pts	62.0	243	2025-12-31
Solvency, sleeve percentile 26.3						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		5.18	(0.31)	18.1	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Current ratio		5.25x	2.96x	34.4	839	2025-12-31
Growth and financing, sleeve percentile 17.7						
Revenue growth, three-year compound		28.3%	10.0%	23.2	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			four consecutive annual FCF observations are required; found 0
Reinvestment rate		not computable	37.1%			one or more required annual facts are missing
Asset growth, three years		16.9%	2.1%	24.3	704	2025-12-31
Net share issuance, one year		(3.2%)	2.5%	5.5	634	2026-02-25

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
60	Ensign Group, Inc. (ENSG)	15.9	A	fortress
61	RxSight, Inc. (RXST)	16.2	A	balance sheet fortress
62	Definium Therapeutics, Inc. (DFTX)	16.5	A	balance sheet dilution
63	Natures Sunshine Products Inc. (NATR)	16.8	A	fortress
64	Alnylam Pharmaceuticals, Inc. (ALNY)	17.0	A	balance sheet
65	Aurinia Pharmaceuticals Inc. (AUPH) <	17.3	A	
66	Acadia Pharmaceuticals Inc. (ACAD)	17.6	A/B	
67	UFP Technologies Inc. (UFPT)	17.8	A/B	
68	Conmed Corp. (CNMD)	18.1	A/B	
69	Dexcom Inc. (DXCM)	18.4	A/B	fortress balance sheet
70	Orthofix Medical Inc. (OFIX)	18.6	A/B	

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	45.8%	8.0%	74
Distance from 52-week high	(12.9%)	(31.4%)	77
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	0.28	0.28	50
Sales to price	0.13	0.31	31
Composite equity issuance, five years	4.3%	20.3%	32
Relative strength against the sector, log excess return	0.16	(0.14)	74

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	pass
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$179.7M
Operating cash flow, four quarters	\$175.2M

Months of runway	not finite
Days since last periodic filing	64 (10-Q received Aug 6, 2026)
Median daily dollar volume, 63 sessions	\$13.4M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$283.1M	2025-12-31	2026-02-26	10-K	0001600620-26-000017
2	cost of revenue	us-gaap:CostOfRevenue	\$32.7M	2025-12-31	2026-02-26	10-K	0001600620-26-000017
3	assets	us-gaap:Assets	\$751.6M	2025-12-31	2026-02-26	10-K	0001600620-26-000017
4	net income	us-gaap:NetIncomeLoss	\$287.2M	2025-12-31	2026-02-26	10-K	0001600620-26-000017
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$135.7M	2025-12-31	2026-02-26	10-K	0001600620-26-000017
6	assets	us-gaap:Assets	\$550.6M	2024-12-31	2026-02-26	10-K	0001600620-26-000017
7	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$235.1M	2024-12-31	2026-02-26	10-K	0001600620-26-000017
8	cost of revenue	us-gaap:CostOfRevenue	\$28.2M	2024-12-31	2026-02-26	10-K	0001600620-26-000017
9	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$175.5M	2023-12-31	2026-02-26	10-K	0001600620-26-000017
10	cost of revenue	us-gaap:CostOfRevenue	\$14.1M	2023-12-31	2026-02-26	10-K	0001600620-26-000017
11	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$134.0M	2022-12-31	2025-02-27	10-K	0001600620-25-000011
12	cost of revenue	us-gaap:CostOfRevenue	\$5.7M	2022-12-31	2025-02-27	10-K	0001600620-25-000011
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$45.6M	2021-12-31	2024-02-15	10-K	0001600620-24-000012
14	cost of revenue	us-gaap:CostOfRevenue	\$1.1M	2021-12-31	2024-02-15	10-K	0001600620-24-000012
15	current assets	us-gaap:AssetsCurrent	\$492.0M	2025-12-31	2026-02-26	10-K	0001600620-26-000017
16	current liabilities	us-gaap:LiabilitiesCurrent	\$93.7M	2025-12-31	2026-02-26	10-K	0001600620-26-000017
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$649.4M	2025-12-31	2026-02-26	10-K	0001600620-26-000017
18	operating income	us-gaap:OperatingIncomeLoss	\$104.9M	2025-12-31	2026-02-26	10-K	0001600620-26-000017
19	book equity	us-gaap:StockholdersEquity	\$581.3M	2025-12-31	2026-02-26	10-K	0001600620-26-000017
20	liabilities	us-gaap:Liabilities	\$170.3M	2025-12-31	2026-02-26	10-K	0001600620-26-000017
21	operating income	us-gaap:OperatingIncomeLoss	-\$91.7M	2023-12-31	2026-02-26	10-K	0001600620-26-000017
22	interest expense	us-gaap:InterestExpense	\$2.8M	2023-12-31	2024-02-15	10-K	0001600620-24-000012
23	assets	us-gaap:Assets	\$548.1M	2023-12-31	2025-02-27	10-K	0001600620-25-000011
24	assets	us-gaap:Assets	\$470.9M	2022-12-31	2024-02-15	10-K	0001600620-24-000012
25	shares outstanding	dei:EntityCommonStockSharesOutstanding	132,970,979	2026-02-25	2026-02-26	10-K	0001600620-26-000017
26	shares outstanding	dei:EntityCommonStockSharesOutstanding	137,339,016	2025-02-25	2025-02-27	10-K	0001600620-25-000011